(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.22%) $78.31
(1.05%) $2.22
(-0.40%) $2 321.90
(-0.42%) $27.50
(2.45%) $988.55
(0.17%) $0.930
(0.76%) $10.91
(0.43%) $0.799
(-0.07%) $91.28
Quarter results today
(bmo 2024-05-07)
Expected move: +/- 10.17%
-7.26% $ 12.01
@ $0.740
Emitido: 13 feb 2024 @ 12:37
Retorno: 1 523.19%
Señal anterior: feb 13 - 11:13
Señal anterior:
Retorno: 0.58 %
Live Chart Being Loaded With Signals
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies...
Stats | |
---|---|
Volumen de hoy | 1.27M |
Volumen promedio | 800 355 |
Capitalización de mercado | 243.62M |
EPS | $0 ( 2024-03-14 ) |
Próxima fecha de ganancias | ( $-3.10 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.870 |
ATR14 | $0.0430 (0.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-03 | Armen Garo H | Buy | 1 248 | Common Stock |
2024-02-05 | Hirsch Susan B | Buy | 5 000 | Stock Option |
2024-02-05 | Wiinberg Ulf | Buy | 5 000 | Stock Option |
2024-02-05 | Corvese Brian | Buy | 15 000 | Stock Option |
2024-02-05 | Jeynes-ellis Allison M | Buy | 5 000 | Stock Option |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 11 180 436 | Sell: 367 647 |
Volumen Correlación
Agenus Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
BTTX | 0.967 |
OMCL | 0.963 |
CDMO | 0.962 |
SCPH | 0.961 |
SVRE | 0.957 |
SILK | 0.957 |
OMER | 0.956 |
LIFE | 0.951 |
CFRX | 0.951 |
CVAC | 0.951 |
10 Correlaciones Más Negativas | |
---|---|
FRSG | -0.974 |
IVCB | -0.973 |
TBSA | -0.97 |
LEGA | -0.968 |
CPAQ | -0.968 |
AHRN | -0.967 |
LGAC | -0.967 |
FTPA | -0.967 |
ACQR | -0.966 |
HORI | -0.966 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Agenus Inc Correlación - Moneda/Commodity
Agenus Inc Finanzas
Annual | 2023 |
Ingresos: | $156.31M |
Beneficio Bruto: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2023 |
Ingresos: | $156.31M |
Beneficio Bruto: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2022 |
Ingresos: | $98.02M |
Beneficio Bruto: | $-99.24M (-101.24 %) |
EPS: | $-0.960 |
FY | 2021 |
Ingresos: | $295.67M |
Beneficio Bruto: | $113.59M (38.42 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico